Literature DB >> 34654937

RIPK3 signaling and its role in the pathogenesis of cancers.

Shanhui Liu1, Kanak Joshi1, Mitchell F Denning1, Jiwang Zhang2,3.   

Abstract

RIPK3 (receptor-interacting protein kinase 3) is a serine/threonine-protein kinase. As a key component of necrosomes, RIPK3 is an essential mediator of inflammatory factors (such as TNFα-tumor necrosis factor α) and infection-induced necroptosis, a programmed necrosis. In addition, RIPK3 signaling is also involved in the regulation of apoptosis, cytokine/chemokine production, mitochondrial metabolism, autophagy, and cell proliferation by interacting with and/or phosphorylating the critical regulators of the corresponding signaling pathways. Similar to apoptosis, RIPK3-signaling-mediated necroptosis is inactivated in most types of cancers, suggesting RIPK3 might play a critical suppressive role in the pathogenesis of cancers. However, in some inflammatory types of cancers, such as pancreatic cancers and colorectal cancers, RIPK3 signaling might promote cancer development by stimulating proliferation signaling in tumor cells and inducing an immunosuppressive response in the tumor environment. In this review, we summarize recent research progress in the regulators of RIPK3 signaling, and discuss the function of this pathway in the regulation of mixed lineage kinase domain-like (MLKL)-mediated necroptosis and MLKL-independent cellular behaviors. In addition, we deliberate the potential roles of RIPK3 signaling in the pathogenesis of different types of cancers and discuss the potential strategies for targeting this pathway in cancer therapy.
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  Cancer pathogenesis; MLKL necroptosis; MLKL-independent signaling; RIPK3 signaling

Mesh:

Substances:

Year:  2021        PMID: 34654937      PMCID: PMC9044760          DOI: 10.1007/s00018-021-03947-y

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.207


  216 in total

1.  Microarray analysis of promoter methylation in lung cancers.

Authors:  Masayuki Fukasawa; Mika Kimura; Sumiyo Morita; Kenichi Matsubara; Sumitaka Yamanaka; Chiaki Endo; Akira Sakurada; Masami Sato; Takashi Kondo; Akira Horii; Hiroyuki Sasaki; Izuho Hatada
Journal:  J Hum Genet       Date:  2006-01-25       Impact factor: 3.172

2.  Structures of CYLD USP with Met1- or Lys63-linked diubiquitin reveal mechanisms for dual specificity.

Authors:  Yusuke Sato; Eiji Goto; Yuri Shibata; Yuji Kubota; Atsushi Yamagata; Sakurako Goto-Ito; Keiko Kubota; Jun-ichiro Inoue; Mutsuhiro Takekawa; Fuminori Tokunaga; Shuya Fukai
Journal:  Nat Struct Mol Biol       Date:  2015-02-16       Impact factor: 15.369

3.  Active MLKL triggers the NLRP3 inflammasome in a cell-intrinsic manner.

Authors:  Stephanie A Conos; Kaiwen W Chen; Dominic De Nardo; Hideki Hara; Lachlan Whitehead; Gabriel Núñez; Seth L Masters; James M Murphy; Kate Schroder; David L Vaux; Kate E Lawlor; Lisa M Lindqvist; James E Vince
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-17       Impact factor: 11.205

4.  Positive and negative phosphorylation regulates RIP1- and RIP3-induced programmed necrosis.

Authors:  Thomas McQuade; Youngsik Cho; Francis Ka-Ming Chan
Journal:  Biochem J       Date:  2013-12-15       Impact factor: 3.857

Review 5.  Necroptosis in development, inflammation and disease.

Authors:  Ricardo Weinlich; Andrew Oberst; Helen M Beere; Douglas R Green
Journal:  Nat Rev Mol Cell Biol       Date:  2016-12-21       Impact factor: 94.444

6.  Diverse sequence determinants control human and mouse receptor interacting protein 3 (RIP3) and mixed lineage kinase domain-like (MLKL) interaction in necroptotic signaling.

Authors:  Wanze Chen; Zhenru Zhou; Lisheng Li; Chuan-Qi Zhong; Xinru Zheng; Xiurong Wu; Yingying Zhang; Huan Ma; Deli Huang; Wenjuan Li; Zongping Xia; Jiahuai Han
Journal:  J Biol Chem       Date:  2013-04-23       Impact factor: 5.157

7.  Ubiquitination of RIP is required for tumor necrosis factor alpha-induced NF-kappaB activation.

Authors:  Hongxiu Li; Masayuki Kobayashi; Marzenna Blonska; Yun You; Xin Lin
Journal:  J Biol Chem       Date:  2006-03-16       Impact factor: 5.157

8.  Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3.

Authors:  Huayi Wang; Liming Sun; Lijing Su; Josep Rizo; Lei Liu; Li-Feng Wang; Fu-Sheng Wang; Xiaodong Wang
Journal:  Mol Cell       Date:  2014-04-03       Impact factor: 17.970

9.  Low expression of mixed lineage kinase domain-like protein is associated with poor prognosis in ovarian cancer patients.

Authors:  Ling He; Kuan Peng; Yizhi Liu; Jing Xiong; Fu-Fan Zhu
Journal:  Onco Targets Ther       Date:  2013-10-30       Impact factor: 4.147

10.  Key roles of necroptotic factors in promoting tumor growth.

Authors:  Xinjian Liu; Min Zhou; Ling Mei; Jiaying Ruan; Qian Hu; Jing Peng; Hang Su; Hong Liao; Shanling Liu; WeiPing Liu; He Wang; Qian Huang; Fang Li; Chuan-Yuan Li
Journal:  Oncotarget       Date:  2016-04-19
View more
  3 in total

1.  Necroptosis-Related Genes Associated With Immune Activity and Prognosis of Colorectal Cancer.

Authors:  Xinyi Peng; Zhili Xu; Yong Guo; Ying Zhu
Journal:  Front Genet       Date:  2022-06-16       Impact factor: 4.772

2.  MLKL deficiency in BrafV600EPten-/- melanoma model results in a modest delay of nevi development and reduced lymph node dissemination in male mice.

Authors:  Sofie Martens; Nozomi Takahashi; Gillian Blancke; Niels Vandamme; Hanne Verschuere; Tatyana Divert; Marnik Vuylsteke; Geert Berx; Peter Vandenabeele
Journal:  Cell Death Dis       Date:  2022-04-14       Impact factor: 9.685

3.  Prognosis analysis of necroptosis-related genes in colorectal cancer based on bioinformatic analysis.

Authors:  Xiaojie Liang; Zhaoxiang Cheng; Xinhao Chen; Jun Li
Journal:  Front Genet       Date:  2022-08-15       Impact factor: 4.772

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.